In August 2025, Wegovy became the first GLP-1 receptor agonist approved for treating MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis in adults without cirrhosis
While we did not measure insulin levels or resistance markers (eg, HOMA-IR), previous trials have demonstrated that semaglutide improves insulin sensitivity independently of weight loss, possibly through reductions in hepatic steatosis and low-grade inflammation
You can also fill out an online rate form to receive the best options available in your area.
If you found this article helpful, then please share with your friends, family, and coworkers by email, twitter, or Facebook
Typically, Vitamin B12 will be given to the shoulder muscle in our office